95 related articles for article (PubMed ID: 16935209)
1. Corticosteroids as antiangiogenic agents.
Oliver A; Ciulla TA
Ophthalmol Clin North Am; 2006 Sep; 19(3):345-51, v. PubMed ID: 16935209
[TBL] [Abstract][Full Text] [Related]
2. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
3. Ocular neovascularization: basic mechanisms and therapeutic advances.
Dorrell M; Uusitalo-Jarvinen H; Aguilar E; Friedlander M
Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S3-19. PubMed ID: 17240254
[TBL] [Abstract][Full Text] [Related]
4. Retinal and choroidal microangiopathies: therapeutic opportunities.
Afzal A; Shaw LC; Ljubimov AV; Boulton ME; Segal MS; Grant MB
Microvasc Res; 2007; 74(2-3):131-44. PubMed ID: 17585951
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in drug delivery systems for treating ocular complications of systemic diseases.
Lee SS; Hughes PM; Robinson MR
Curr Opin Ophthalmol; 2009 Nov; 20(6):511-9. PubMed ID: 19667987
[TBL] [Abstract][Full Text] [Related]
6. Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration.
Ambrus JL; Toumbis CA; Karakousis CP; Kulaylat M; Akhter S; Plavsic L
J Med; 2000; 31(5-6):278-82. PubMed ID: 11508321
[TBL] [Abstract][Full Text] [Related]
7. Calcitriol is a potent inhibitor of retinal neovascularization.
Albert DM; Scheef EA; Wang S; Mehraein F; Darjatmoko SR; Sorenson CM; Sheibani N
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2327-34. PubMed ID: 17460298
[TBL] [Abstract][Full Text] [Related]
8. Combination angiostatic therapies: targeting multiple angiogenic pathways.
Friedlander M
Retina; 2009 Jun; 29(6 Suppl):S27-9. PubMed ID: 19553794
[TBL] [Abstract][Full Text] [Related]
9. Drops for corneal neovascularization.
Das M; Murthy S
Ophthalmology; 2010 Oct; 117(10):2042; author reply 2042-3. PubMed ID: 20888488
[No Abstract] [Full Text] [Related]
10. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.
Hosseini H; Nejabat M
Med Hypotheses; 2007; 68(4):799-801. PubMed ID: 17107753
[TBL] [Abstract][Full Text] [Related]
11. The role of integrin alpha5beta1 in the regulation of corneal neovascularization.
Muether PS; Dell S; Kociok N; Zahn G; Stragies R; Vossmeyer D; Joussen AM
Exp Eye Res; 2007 Sep; 85(3):356-65. PubMed ID: 17659277
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.
Aydin E; Kivilcim M; Peyman GA; Esfahani MR; Kazi AA; Sanders DR
Cornea; 2008 May; 27(4):446-53. PubMed ID: 18434849
[TBL] [Abstract][Full Text] [Related]
13. Ocular angiogenesis: the role of growth factors.
Kvanta A
Acta Ophthalmol Scand; 2006 Jun; 84(3):282-8. PubMed ID: 16704684
[TBL] [Abstract][Full Text] [Related]
14. Recent drug therapies for corneal neovascularization.
Liu X; Wang S; Wang X; Liang J; Zhang Y
Chem Biol Drug Des; 2017 Nov; 90(5):653-664. PubMed ID: 28489275
[TBL] [Abstract][Full Text] [Related]
15. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization.
Li WW; Casey R; Gonzalez EM; Folkman J
Invest Ophthalmol Vis Sci; 1991 Oct; 32(11):2898-905. PubMed ID: 1917393
[TBL] [Abstract][Full Text] [Related]
16. Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis).
Stout JT
Trans Am Ophthalmol Soc; 2006; 104():530-60. PubMed ID: 17471360
[TBL] [Abstract][Full Text] [Related]
17. [Molecular aspects of corneal neovascularization].
Krawczyk P; Ambroziak AM; Szaflik JP
Klin Oczna; 2014; 116(3):210-4. PubMed ID: 25799787
[TBL] [Abstract][Full Text] [Related]
18. Pfaffia paniculata (Brazilian ginseng) methanolic extract reduces angiogenesis in mice.
Carneiro CS; Costa-Pinto FA; da Silva AP; Pinello KC; da Silva TC; Matsuzaki P; Nagamine MK; Górniak SL; Haraguchi M; Akisue G; Dagli ML
Exp Toxicol Pathol; 2007 Aug; 58(6):427-31. PubMed ID: 17481871
[TBL] [Abstract][Full Text] [Related]
19. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
Khalaim AV; Stoliarenko GE
Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
[No Abstract] [Full Text] [Related]
20. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
